Emergent BioSolutions Inc. announced a contract modification to deliver CNJ-016 (Vaccinia Immune Globulin Intravenous (Human), or VIGIV) to the Administration for Strategic Preparedness and Response (ASPR). This award, part of U.S. biodefense preparedness efforts, is for smallpox preparedness.
ASPR exercised an option from its existing 10-year contract for additional doses of VIGIV, which is a treatment for complications arising from vaccinia vaccination. This contract modification underscores Emergent’s ongoing partnership with the U.S. government to support its overall smallpox preparedness strategy.
Emergent is committed to fulfilling its mission to protect and save lives by providing diverse medical countermeasures through its North American supply chain and capabilities for stockpiling. This ensures readiness to address public health threats in the United States and globally.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.